NASDAQ:IRON News 19 December 2025 - 1 January 2026

Disc Medicine shares rose 3.3% to $79.41 in the final 2025 U.S. trading session, ahead of an FDA decision expected by late January on its lead drug bitopertin for EPP. The stock has been volatile since reports of FDA skepticism on efficacy. No new company announcements were made. Broader biotech indexes ended mixed as markets closed for the New Year’s holiday.

Disc Medicine, Inc. stock (NASDAQ: IRON) sank sharply on Friday, Dec. 19, 2025, with IRON down about 10% in late-morning trading and swinging through a wide intraday range that, at one point, dipped into the low $70s before rebounding toward the low $80s. MarketScreener The timing matters: the selloff arrives just weeks before investors expect clarity on Disc’s most important near-term catalyst—an FDA decision on bitopertin for erythropoietic protoporphyria (EPP)—and amid a burst of insider-trading disclosures and Form 144 filings that can spook momentum-driven biotech traders even when sales are planned. MarketBeat+1 Below is a full, up-to-date roundup of what’s